Literature DB >> 35925357

[Anti-VEGF (anti-vascular endothelial growth factor) treatment for central vein occlusion during breastfeeding].

S Groselli1, L Bechstein2, K Gabka2, M Ulbig2.   

Abstract

Entities:  

Year:  2022        PMID： 35925357     DOI： 10.1007/s00347-022-01694-4

Source DB:  PubMed          Journal:  Ophthalmologie        ISSN： 2731-720X


× No keyword cloud information.
  8 in total

1.  BEVACIZUMAB LEVELS IN BREAST MILK AFTER LONG-TERM INTRAVITREAL INJECTIONS.

Authors:  Trevor J McFarland; Andrew D Rhoads; Matthew Hartzell; Geoffrey G Emerson; Abdhish R Bhavsar; J Timothy Stout
Journal:  Retina       Date:  2015-08       Impact factor: 4.256

2.  Reduction of vascular endothelial growth factor a in human breast milk after intravitreal injection of bevacizumab but not ranibizumab.

Authors:  Christoph Ehlken; Gottfried Martin; Andreas Stahl; Hansjürgen Thomas Agostini
Journal:  Arch Ophthalmol       Date:  2012-09

3.  Ranibizumab and Aflibercept Levels in Breast Milk after Intravitreal Injection.

Authors:  Verena R Juncal; Quratulain Paracha; Motaz Bamakrid; Carolina L M Francisconi; Julia Farah; Amin Kherani; Rajeev H Muni
Journal:  Ophthalmology       Date:  2019-09-12       Impact factor: 12.079

4.  REVIEW OF OPHTHALMIC AND BREASTFEEDING MEDICINE EVIDENCE: Real and Theoretical Risks of Intravitreal Anti-Vascular Endothelial Growth Factor Administration in Lactating Women.

Authors:  Prarthana J Dalal; Aloka L Patel; Michelle Carle; Alekya Rajanala; Manjot K Gill
Journal:  Retina       Date:  2020-11       Impact factor: 4.256

5.  Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial.

Authors:  Andreas Stahl; Domenico Lepore; Alistair Fielder; Brian Fleck; James D Reynolds; Michael F Chiang; Jun Li; Melissa Liew; Rainer Maier; Qi Zhu; Neil Marlow
Journal:  Lancet       Date:  2019-09-12       Impact factor: 79.321

6.  Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD.

Authors:  Robert L Avery; Alessandro A Castellarin; Nathan C Steinle; Dilsher S Dhoot; Dante Joseph Pieramici; Robert See; Stephen Couvillion; Ma'an A Nasir; Melvin D Rabena; Kha Le; Mauricio Maia; Jennifer E Visich
Journal:  Br J Ophthalmol       Date:  2014-07-07       Impact factor: 4.638

7.  Ranibizumab Population Pharmacokinetics and Free VEGF Pharmacodynamics in Preterm Infants With Retinopathy of Prematurity in the RAINBOW Trial.

Authors:  Matthew Fidler; Brian W Fleck; Andreas Stahl; Neil Marlow; James E Chastain; Jun Li; Domenico Lepore; James D Reynolds; Michael F Chiang; Alistair R Fielder
Journal:  Transl Vis Sci Technol       Date:  2020-07-29       Impact factor: 3.283
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.